anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Genome-wide association studies (GWASs) based on common single nucleotide polymorphisms (SNPs) have identified several loci associated with the risk of monoclonal gammopathy of unknown significance (MGUS), a precursor condition for multiple myeloma (MM). We hypothesized that analyzing haplotypes might be more useful than analyzing individual SNPs, as it could identify functional chromosomal units that collectively contribute to MGUS risk. To test this hypothesis, we used data from our previous GWAS on 992 MGUS cases and 2910 controls from three European populations. We identified 23 haplotypes that were associated with the risk of MGUS at the genome-wide significance level (p < 5 × 10-8) and showed consistent results among all three populations. In 10 genomic regions, strong promoter, enhancer and regulatory element-related histone marks and their connections to target genes as well as genome segmentation data supported the importance of these regions in MGUS susceptibility. Several associated haplotypes affected pathways important for MM cell survival such as ubiquitin-proteasome system (RNF186, OTUD3), PI3K/AKT/mTOR (HINT3), innate immunity (SEC14L1, ZBP1), cell death regulation (BID) and NOTCH signaling (RBPJ). These pathways are important current therapeutic targets for MM, which may highlight the advantage of the haplotype approach homing to functional units.
As of March 22, 2020, a total of 311,988 people worldwide have been diagnosed with a respiratory infection caused by SARS-CoV-2 of whom 13,407 have died. In the United States 26,747 patients have tested positive of whom 340 have died. There is at present no established therapy for this infection. After the SARS epidemic in 2002, investigations identified chloroquine as a possible inhibitor of replication of this coronavirus. When the SARS-CoV-2 epidemic started in December of 2019, clinicians began to use chloroquine in an attempt to control the infection in newly diagnosed patients. Investigators from China reported chloroquine phosphate has apparent efficacy in treatment of pneumonia due to SARS-CoV-2. Following this report, investigators in France initiated an open label study of hydroxychloroquine, with the addition of azithromycin, in a small number of subjects with SARS-CoV-2 infection. Relative to no treatment the investigators identified a significant reduction in viral isolation by PCR in the nasal swabs of treated patients, with an additional effect seen when patients were also given azithromycin. Azithromycin, like chloroquine, is a weak base that concentrates in endosomes and lysosomes and raises the pH in those vesicles. It is possible that azithromycin and chloroquine's effect on endosomal processing reduces the inflammatory response by affecting TLR4 signaling through the endosomes.
This invention relates to a safe carrier for the seed viruses of inactivated vaccine for the foot-and-mouth disease and the application thereof. Different serum-type seed viruses for producing the inactivated vaccines for the foot-and-mouth disease safely are constructed on the basis of the carrier. The constructed embedded viruses retain the advantage of good adaptability of the classic vaccine virus strain cell, overcome the defect of low matching performance of the antigen through the structural protein inserted into the epidemic virus strain and can save virus quickly to produce the inactivated vaccine for foot-and-mouth disease. The A or Asia I or O type different virus-strain embedded viruses which are constructed through the carrier are less virulent and have good bio-security. Because the viruses are short of the protein L, the virulence of the viruses can not become stronger under the natural condition, and the pathogenicity of the viruses on the neonatal rat, pig or cow is reduced greatly or the viruses are not pathogenic. The carrier is highly safe, can not cause the foot-and-mouth disease and is highly practical.
The present invention relates to a stable sterilized parenteral formulation comprising an acid susceptible proton pump inhibitor. The formulation, a solid formulation comprising the acid susceptible proton pump inhibitor and optionally pharmaceutically acceptable excipients, has been sterilized in its final container by ionizing radiation. The container may consist of several compartments and separately contains a suitable solvent, which is sterilized, i.e. radiated, at the same time as the solid formulation. Alternatively, the suitable solvent is sterilized separately or aseptically manufactured. The solid formulation is dissolved in a suitable solvent before being administered to the patient, i.e. being prepared ex tempore. The present invention also relates to the prepared sterilized parenteral formulation, the stable solid formulation, processes for obtaining said parenteral formulation and the solid formulation as well as to the therapeutic uses thereof.
Mechanical neck pain is a prevalent condition in various populations. Neck pain occurrence is affected by several factors, involving environmental, psychological, and social aspects. Neck pain represents the fourth major disorder responsible for a person's year lived with disability and ranked eleventh as disability-adjusted life years of a person. The neck pain incidence ranges from 10.4 to 23.3% in 1-year time, while the range of prevalence was 0.4 to 86.8%. It has a high prevalence among computer users, office workers, and females, especially females aged 35 to 49 years old. Myofascial trigger point (MTrP) might play an important role in the formation of mechanical neck pain and is known as a hyperirritable spot in skeletal muscle that is accompanied with a hypersensitive palpable nodule in a taut band.

dry needling and iontophoresis play a major role in the treatment of mechanical neck pain so this trial was conducted to determine which one has superiority. this trial has three groups. two experimental and one control group.pain, function, pressure pain threshold and emg will be measured
MAP was kept between 65 and 90 mmHg, CVP between 8 and 12 mmHg and urinary output more than 0.5 ml•kg-1•h-1. 500 ml of crystalloids was infused during induction, followed by a continuous infusion of crystalloids (4 ml•kg-1•h-1). If the MAP decreased below 65 mmHg, or if the CVP decreased below 8 mmHg, a 250 mL bolus of colloid was given after waiting 5 minutes if any one of the criteria was met. If the MAP decreased below 65 mmHg and remained unresponsive to fluids, norepinephrine or inotropes was given to maintain the MAP above 65 mmHg.
Enalapril and hydrochlorothiazide are effective treatments for hypertension. The usual dosage range of enalapril is 10 to 40 mg per day administered in a single or two divided doses; hydrochlorothiazide is effective in doses of 12.5 to 50 mg daily. The side effects (see WARNINGS) of enalapril are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of enalapril and hydrochlorothiazide will be associated with both sets of dose-independent side effects but the addition of enalapril in clinical trials blunted the hypokalemia normally seen with diuretics. To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.

Dose Titration Guided by Clinical Effect: A patient whose blood pressure is not adequately controlled with either enalapril or hydrochlorothiazide monotherapy may be given VASERETIC 10-25 mg. Further increases of enalapril, hydrochlorothiazide or both depend on clinical response. The hydrochlorothiazide dose should generally not be increased until 2-3 weeks have elapsed. In general, patients do not require doses in excess of 20 mg of enalapril or 50 mg of hydrochlorothiazide. The daily dosage should not exceed two tablets of VASERETIC 10-25 mg.

Replacement Therapy: The combination may be substituted for the titrated components.

Use in Renal Impairment: The usual regimens of therapy with VASERETIC need not be adjusted as long as the patient's creatinine clearance is greater than 30 mL/min/1.73 m2 (serum creatinine approximately less than or equal to 3 mg/dL or 265 µmol/L). In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so enalapril maleate and hydrochlorothiazide is not recommended (see WARNINGS, Anaphylactoid Reactions During Membrane Exposure).
The disclosure relates to the use of aniline or a salt or derivative thereof selected from the group consisting of 4-methoxyaniline, 4-nitroaniline, 2,6-dimethylaniline, a deuterated aniline derivative or a polymer-bound aniline, as a radiostabilizer in a method comprising the step of reacting a radiolabeled aldehyde (I) with an aminooxy (II) in the presence of aniline (III) to form imine-oxy (IV) (abstract figure). The method is performed at a pH of about 1.0-7.0, and the starting activity of the radiolabeled aldehyde (I) is at least 50 GBq. The radiolabelled aldehyde may further contain a radiolabelled organic or biological moiety, such as alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, cycloalkyl, amino acid, peptide, or vector moieties. The radiolabel may be radioisotope suitable for PET or SPECT imaging. The aminooxy may further contain any organic or biological moiety. The disclosure also relates to the use of aniline as a radiostabilizer in a method comprising the step of reacting a aldehyde with a radiolabeled aminooxy to form an imine-oxy.
Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
PURPOSE:An ointment base having improved solubility and dispersibility of drug, etc. and transmigration to the affected part whose sufficient improved effects are not obtained by a well-known solvent, obtained by using a specific cyclic urea derivative as a solvent for a medicinal component. CONSTITUTION:An ointment component consisting essentially of petrolatum, polysiloxane, etc. is blended with usually about 0.1-30wt%, preferably about 0.5-10wt% based on the ointment base of a cyclic urea derivative shown by the formula I (X<1> and X<2> are lower alkyl, or lower alkenyl; X<3> is H, or lower alkyl; n is 1 or 2; when X<1> and X<2> are lower alkyl, and n is 1, X<3> is not H), preferably a compound shown the formula II so that dispersibility and solubility of a medicinal component in the ointment base and transmigration to the affected part, etc. are improved, and remedying effects of the medicinal component are sufficiently shown. The ointment base can be optionally blended with a surface active agent, a thickening agent, a penetrant, an auxiliary, a preservative, an antioxidant, etc.
The concentrates include compsns. for dyeing, permanently waving, straightening or bleaching hair, contg. alkali NH3, mercapto carboxylic acid salts or esters or H2O2. Process allows prepn. of highly dilutable concentrates which can be diluted to 5-20x of original liquid vol. without hazards, e.g. skin irritation damage to clothes, furniture and floors. Wadding may consist of natural, artificial and/or synthetic fibres, e.g. cotton wool, viscose or acetate rayon polyethylene, polypropylene, PTFE, polyester, PVC polyamide, polyurethane, and/or polyacrylonitrile. The concentrates can be packed in glass or plastic containers or sachets of plastic-lined Al foil. After dilution, the pad may be used to apply to soln.
Participants ≤11 to \<25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
COPD patients aged 40 or more, with a smoking history of \> 10 PY and a post-bronchodilator FEV1/VC \< 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
BACKGROUND AND OBJECTIVES: Total Plaque Area (TPA) measurement is critical for early diagnosis and intervention of carotid atherosclerosis in individuals with high risk for stroke. The delineation of the carotid plaques is necessary for TPA measurement, and deep learning methods can automatically segment the plaque and measure TPA from carotid ultrasound images. A large number of labeled images is essential for training a good deep learning model, but it is very difficult to collect such large labeled datasets for carotid image segmentation in clinical practice. Self-supervised learning can provide a possible solution to improve the deep-learning models on small labeled training datasets by designing a pretext task to pre-train the models without using the segmentation masks. However, the existing self-supervised learning methods do not consider the feature presentations of object contours.
METHODS: In this paper, we propose an image registration-based self-supervised learning method and a stacked U-Net (SSL-SU-Net) for carotid plaque ultrasound image segmentation, which can better exploit the semantic features of carotid plaque contours in self-supervised task training.
RESULTS: Our network was trained on different numbers of labeled images (n = 10, 33, 50 and 100 subjects) and tested on 44 subjects from the SPARC dataset (n = 144, London, Canada). The network trained on the entire SPARC dataset was then directly applied to an independent dataset collected in Zhongnan hospital (n = 497, Wuhan, China). For the 44 subjects tested on the SPARC dataset, our method yielded a DSC of 80.25-89.18% and the produced TPA measurements, which were strongly correlated with manual segmentation (r = 0.965-0.995, ρ< 0.0001). For the Zhongnan dataset, the DSC was 90.3% and algorithm TPAs were strongly correlated with manual TPAs (r = 0.985, ρ< 0.0001).
CONCLUSIONS: The results demonstrate that our proposed method yielded excellent performance and good generalization ability when trained on a small labeled dataset, facilitating the use of deep learning in carotid ultrasound image analysis and clinical practice. The code of our algorithm is available https://github.com/a610lab/Registration-SSL.
BACKGROUND: Positive effects of RNS60 on respiratory and bulbar function were observed in a phase 2 randomized, placebo-controlled trial in people with amyotrophic lateral sclerosis (ALS).
OBJECTIVE: to investigate the long-term survival of trial participants and its association with respiratory status and biomarkers of neurodegeneration and inflammation.
STUDY DESIGN AND SETTINGS: A randomized, double blind, phase 2 clinical trial was conducted. Trial participants were enrolled at 22 Italian Expert ALS Centres from May 2017 to January 2020. Vital status of all participants was ascertained thirty-three months after the trial's last patient last visit (LPLV). Participants were patients with Amyotrophic Lateral Sclerosis, classified as slow or fast progressors based on forced vital capacity (FVC) slope during trial treatment. Demographic, clinical, and biomarker levels and their association with survival were also evaluated.
RESULTS: Mean duration of follow-up was 2.8 years. Long-term median survival was six months longer in the RNS60 group (p = 0.0519). Baseline FVC, and rates of FVC decline during the first 4 weeks of trial participation, were balanced between the active and placebo treatment arms. After 6 months of randomized, placebo-controlled treatment, FVC decline was significantly slower in the RNS60 group compared to the placebo group. Rates of FVC progression during the treatment were strongly associated with long-term survival (median survival: 3.7 years in slow FVC progressors; 1.6 years in fast FVC progressors). The effect of RNS60 in prolonging long-term survival was higher in participants with low neurofilament light chain (NfL) (median survival: >4 years in low NfL - RNS60 group; 3.3 years in low NfL - placebo group; 1.9 years in high NfL - RNS60 group; 1.8 years in high NfL - placebo group) and Monocyte Chemoattractant Protein-1 (MCP-1) (median survival: 3.7 years in low MCP-1 - RNS60 group; 2.3 years in low MCP-1 - placebo group; 2.8 years in high MCP-1 - RNS60 group; 2.6 years in high MCP-1 - placebo group) levels at baseline.
CONCLUSIONS AND RELEVANCE: In this post-hoc analysis, long term survival was longer in participants randomized to RNS60 compared with those randomized to placebo and was correlated with slower FVC progression rates, suggesting that longer survival may be mediated by the drug's effect on respiratory function. In these post-hoc analyses, the beneficial effect of RNS60 on survival was most pronounced in participants with low NfL and MCP-1 levels at study entry, suggesting that this could be a subgroup to target in future studies investigating the effects of RNS60 on survival.
TRIAL REGISTRATION: Study preregistered on 13/Jan/2017 in EUDRA-CT (2016-002382-62). The study was also registered at ClinicalTrials.gov number NCT03456882.
Example embodiments of the described technology provide a method for adaptive dual-energy imaging. The method comprises a calibrating a fitting model and implementing the calibrated model. Calibrating the fitting model comprises acquiring high energy and low energy images of a step phantom, generating regions of interest with overlapping materials, and determining an average intensity for each region of interest in each of the high energy and low energy images. Calibrating the fitting model further comprises determining a model material cancellation weighting factor and a model noise cancellation weighting factor for each of a first material and a second material for each of the regions of interest. The weighting factors are fit to a fitting model as a function of the signal intensities of the high energy and low energy images. Implementing the calibrated model comprises acquiring high energy and low energy images of a subject and generating maps of a subject-specific material cancellation weighting factor and a subject-specific noise cancellation weighting factor according to the fitting model. Implementing the calibrated model further comprises applying the maps of the subject-specific material cancellation weighting factor and the subject-specific noise cancellation weighting factor to the high and low energy images of the subject.
As the richest source of astaxanthin, a natural antioxidant and coloring agent, the unicellular green alga, Haematococcus pluvialis, is being commercially exploited. A major constraint in the Haematococcus production system, however, is the thick, rigid cell walls associated with astaxanthin-rich cysts (or aplanospores). The thick walls prevent the extraction of cellular materials and consequently reduce the bioavailability of astaxanthin. Using a physical, chemical, or enzymatic method to disrupt the cell wall has proven to be very expensive and also introduce the risk of oxidation of astaxanthin by atmospheric oxygen The present invention provides a novel method for solving this problem by introducing two genetically modified Haematococcus pluvialis mutants. These two mutants, named as D 13- 17 and N54-22, contain remarkably reduced amounts of cell wall materials, but retain the growth potential and ability to accumulate astaxanthin as high as the wild type strain. Organic solvent extraction efficiency assay has demonstrated that cellular astaxanthin can be more effectively and efficiently extracted from the cell wall-deficient mutants than from the wild type, suggesting that the mutants may provide better bioavailability of astaxanthin to humans and animals. The said mutants can be used for production of natural astaxanthin for human and animal consumption
Cyproheptadine is a serotonin and histamine antagonist with anticholinergic and sedative effects. Antiserotonin and antihistamine drugs appear to compete with serotonin and histamine, respectively, for receptor sites.   


After a single 4 mg oral dose of 14C-labelled Cyproheptadine HCl in normal subjects, given as tablets, 2-20% of the radioactivity was excreted in the stools. Only about 34% of the stool radioactivity was unchanged drug, corresponding to less than 5.7% of the dose. At least 40% of the administered radioactivity was excreted in the urine. No detectable amounts of unchanged drug were present in the urine of patients on chronic 12-20 mg daily doses. The principle metabolite found in human urine has been identified as a quaternary ammonium glucuronide conjugate of cyproheptadine. Elimination is diminished in renal insufficiency. Pharmacokinetics and Metabolism:
Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 \[i.e. Cycles 1, 2, 3, etc.\]) until disease progression or intolerance panitumumab as determined by the investigator.
Rationale: Air pollution is a major risk factor for chronic cardiorespiratory diseases, affecting the immune and respiratory systems' functionality, but epidemiological evidence in respiratory infections remains sparse. Objectives: We aimed to assess the association of long-term exposure to ambient air pollution with the risk of developing new and recurrent acute lower respiratory infections (ALRIs), characterized by persistently severe symptoms necessitating hospital contact, and identify the potential susceptible populations by socioeconomic status, smoking, physical activity status, overweight, and comorbidity with chronic lung disease. Methods: We followed 23,912 female nurses from the Danish Nurse Cohort (age >44 yr) from baseline (1993 or 1999) until 2018 for incident and recurrent ALRIs defined by hospital contact (inpatient, outpatient, and emergency room) data from the National Patient Register. Residential annual mean concentrations of fine particulate matter, nitrogen dioxide (NO2), and black carbon were modeled using the Danish Eulerian Hemispheric Model/Urban Background Model/Air Geographic Information System. We used marginal Cox models with time-varying exposures to assess the association of 3-year running mean air pollution level with incident and recurrent ALRIs and examined effect modification by age, socioeconomic status, smoking, physical activity, body mass index, and comorbidity with asthma or chronic obstructive pulmonary disease (COPD). Results: During a 21.3-year mean follow-up, 4,746 ALRIs were observed, of which 2,553 were incident. We observed strong positive associations of all three pollutants with incident ALRIs, with hazard ratios and 95% confidence intervals of 1.19 (1.08-1.31) per 2.5 μg/m3 for fine particulate matter, 1.17 (1.11-1.24) per 8.0 μg/m3 for NO2, and 1.09 (1.05-1.12) per 0.3 μg/m3 for black carbon, and slightly stronger associations with recurrent ALRIs. Associations were strongest in patients with COPD and nurses with low physical activity. Conclusions: Long-term exposure to air pollution at low levels was associated with risks of new and recurrent ALRIs, with patients with COPD and physically inactive subjects most vulnerable.